Free Trial

Alnylam Pharmaceuticals (ALNY) SEC Filings & 10K Form

Alnylam Pharmaceuticals logo
$452.33 -1.85 (-0.41%)
Closing price 04:00 PM Eastern
Extended Trading
$451.98 -0.35 (-0.08%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Alnylam Pharmaceuticals SEC Filings

DateFilerForm TypeView
08/19/2025
4:26 PM
Alnylam Pharmaceuticals (Issuer)
BONNEY MICHAEL W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025
4:26 PM
Alnylam Pharmaceuticals (Issuer)
Fitzgerald Kevin Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025
4:27 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025
4:27 PM
Alnylam Pharmaceuticals (Issuer)
Poulton Jeffrey V. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025
4:28 PM
Alnylam Pharmaceuticals (Issuer)
Tanguler Tolga (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025
4:28 PM
Alnylam Pharmaceuticals (Issuer)
Garg Pushkal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2025
3:08 PM
Alnylam Pharmaceuticals (Subject)
BONNEY MICHAEL W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/31/2025
7:05 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2025
7:11 AM
Alnylam Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/18/2025
3:48 PM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2025
3:10 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2025
3:18 PM
Alnylam Pharmaceuticals (Subject)
Greenstreet Yvonne (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2025
4:01 PM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2025
7:09 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2025
7:15 AM
Alnylam Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/07/2025
10:51 AM
Alnylam Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SCHEDULE 13G/A
03/24/2025
4:00 PM
Alnylam Pharmaceuticals (Filer)
Form DEFA14A
03/24/2025
4:02 PM
Alnylam Pharmaceuticals (Filer)
Form ARS
03/24/2025
3:40 PM
Alnylam Pharmaceuticals (Filer)
Form DEF 14A
03/24/2025
3:13 PM
Alnylam Pharmaceuticals (Subject)
PYOTT DAVID E I (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/14/2025
3:16 PM
Alnylam Pharmaceuticals (Filer)
Form PRE 14A
03/14/2025
3:16 PM
Alnylam Pharmaceuticals (Issuer)
SCHULMAN AMY W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:31 PM
Alnylam Pharmaceuticals (Issuer)
Garg Pushkal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:31 PM
Alnylam Pharmaceuticals (Issuer)
Tanguler Tolga (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:31 PM
Alnylam Pharmaceuticals (Issuer)
Poulton Jeffrey V. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:32 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2025
1:14 PM
Alnylam Pharmaceuticals (Subject)
Capital Research Global Investors (Filed by)
Form SCHEDULE 13G
02/13/2025
7:31 AM
Alnylam Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/13/2025
7:09 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2025
3:01 PM
Alnylam Pharmaceuticals (Subject)
Garg Pushkal (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2025
3:17 PM
Alnylam Pharmaceuticals (Subject)
SHARP PHILLIP A (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2025
6:31 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/13/2024
3:13 PM
Alnylam Pharmaceuticals (Issuer)
Garg Pushkal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:20 PM
Alnylam Pharmaceuticals (Issuer)
Fitzgerald Kevin Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:21 PM
Alnylam Pharmaceuticals (Issuer)
Tanguler Tolga (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:21 PM
Alnylam Pharmaceuticals (Issuer)
Poulton Jeffrey V. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:22 PM
Alnylam Pharmaceuticals (Issuer)
Garg Pushkal (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
4:22 PM
Alnylam Pharmaceuticals (Issuer)
Greenstreet Yvonne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
3:06 PM
Alnylam Pharmaceuticals (Subject)
Fitzgerald Kevin Joseph (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/08/2024
9:34 AM
Alnylam Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
10/31/2024
7:10 AM
Alnylam Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
NVIDIA's Worst Nightmare? (Ad)

$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the REAL fortune they expect to come from quantum computing - a $2 trillion explosion by 2035. The kicker? One company is America's FIRST commercial supplier of the material that makes it possible.tc pixel

Click here to learn how to get the ticker symbol <<<
10/31/2024
7:22 AM
Alnylam Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/03/2024
3:11 PM
Alnylam Pharmaceuticals (Issuer)
Hesslein Robert W. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ALNY) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners